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factors established in the rat Thy 1 model of mesangiolysis andGrowth factor expression in a murine model of cryoglobuli-
repairs to a murine model of progressive glomerulonephritisnemia.
closely resembling human MPGN.Background. Increased expression of growth factors includ-
ing platelet-derived growth factor (PDGF) and transforming
growth factor-beta (TGF-) are thought to play pivotal roles
during mesangial expansion and glomerulosclerosis. Thymic
Cryoglobulinemia is a systemic disease with a widestromal lymphopoietin (TSLP) transgenic mice develop mixed
spectrum of manifestations [1, 2]. Up to 55% of patientscryoglobulinemia and a membranoproliferative glomerulo-
nephritis (MPGN). Here we describe the renal expression of with mixed cryoglobulinemia develop renal involvement
isoforms of PDGF and TGF- in relation to changes in extra- [1–4]. The typical renal manifestation of mixed cryoglo-
cellular matrix (ECM) components and markers of cell prolifer- bulinemia is a membranoproliferative glomerulonephri-ation and activation in this model.
tis (MPGN) characterized by deposits of immune com-Methods. A total of 123 mice, including 61 TSLP transgenic
mice and 62 wild-type controls, were sacrificed at defined inter- plexes in glomerular capillary walls and mesangial areas,
vals. PDGF-A chain, -B chain, PDGF - and -receptor (-R) increased glomerular cellularity, mesangial matrix accu-
and TGF-1 mRNA were analyzed by in situ hybridization. mulation, and thickening and splitting of peripheral cap-
Expression of  smooth muscle actin (SMA), collagen type I,
illaries. Additionally, intraluminal thrombi composed ofcollagen type IV, laminin, and a marker of proliferating cells
cryoprecipitable immune complexes, monocyte/macro-(PCNA) were assessed by immunohistochemistry. Slides also
were studied by combined immunohistochemistry and in situ phage infiltration, and an organized substructure of the
hybridization with an antibody that recognizes monocytes/mac- immune deposits in the form of microfibrils and/or mi-
rophage and with riboprobes that detect PDGF B-chain, PDGF crotubules are typical morphological features that can
-R or TGF-1 mRNA.
be present in cryoglobulinemic glomerulonephritis [5–7].Results. Increased numbers of proliferating glomerular cells
Extraglomerular microscopic vasculitis also can be pres-appeared early in the disease course, associated with de novo
expression of SMA. Expression of PDGF B-chain and -R ent in same cases. The pathogenesis of this important
mRNA was increased in the mesangium and in parietal epithe- form of glomerular injury is still incompletely understood.
lial cells of TSLP transgenic mice and correlated with the num- Recent studies have demonstrated that platelet-derivedber of PCNA positive cells. Increased TGF-1 mRNA expres-
growth factor (PDGF) and transforming growth factor-sion paralleled the deposition of type IV collagen. A significant
beta (TGF-) may be of major importance for the devel-proportion of Mac-2 positive macrophages expressed TGF-1
mRNA, while only a small percentage of glomerular macro- opment of mesangial expansion and deposition of extra-
phages expressed PDGF B-chain mRNA. No PDGF -R cellular matrix (ECM) in settings of glomerular injury
mRNA expression by macrophages was detected.
[8, 9]. PDGF, which can be released from activated plate-Conclusion. TSLP transgenic mice develop a membrano-
lets, monocytes/macrophages, and mesangial cells, is anproliferative glomerulonephritis in which glomerular cell pro-
liferation and matrix deposition are associated with an in- important mediator of mesangial cell proliferation, and
creased expression of PDGF B-chain, PDGF -R and TGF-1. is involved in ECM expansion [10–15]. TGF- promotes
These findings extend the paradigms covering these growth glomerular injury through the accumulation of ECM,
leading to glomerulosclerosis. Increased synthesis of nor-
mal glomerular ECM components (type IV collagen,Key words: thymic stromal lymphopoietin, glomerulonephritis, cryo-
globulinemia, membranoproliferative glomerulonephritis, PDGF, TGF-. laminin and proteoglycans), abnormal ECM components
(type I and III collagens), as well as reduction of ECM
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stromal cell line, and supports B cell growth and differen- Immunohistochemistry
tiation [20]. We have recently reported that transgenic Four micrometer sections of formalin- and methyl Car-
mice, overexpressing TSLP, develop mixed cryoglobul- noy’s-fixed, paraffin embedded tissue were processed by
ins and MPGN [21]. Renal involvement in TSLP trans- an indirect immunoperoxidase technique as previously
genic mice is characterized by monocyte/macrophage in- described [21, 23]. Sections were deparaffinized in xy-
filtration, marked ECM expansion, increased glomerular lene, rehydrated in graded ethanol and then incubated
cellularity, and prominent accumulation of subendothe- in 3% hydrogen peroxide for five minutes to block en-
lial and mesangial electron-dense deposits closely resem- dogenous peroxidase. Endogenous biotin was blocked
bling the morphological features of human MPGN [21]. using the Avidin-Biotin blocking Kit (Vector Labora-This new model of a membranoproliferative type of glo-
tories, Burlingame, CA, USA). Antigen retrieval wasmerular injury gave us the opportunity to describe the
performed by heat treatment. Sections were sequentiallysequence of cellular events involving the growth factors
incubated with 10% normal serum, the primary antibodymentioned above. We further assessed the expression of
diluted in phosphate-buffered saline (PBS) containingalpha-smooth muscle actin (SMA; a marker of activated
1% bovine serum albumin for one hour, followed by themesangial cells), and accumulations of several compo-
biotinylated secondary antibody (Vector Laboratories),nents of the ECM, and correlated these with the expres-
and the avidin-biotin-horseradish peroxidase (HRP)sion patterns of PDGF and TGF-1. We also evaluated
complex (Vector). The immunoreaction was visualizedmonocyte/macrophage expression of the growth factors
by 3,3-diaminobenzidine (DAB; Sigma, St. Louis, MO,PDGF-B chain and TGF-1, as well as PDGF -receptor
USA) with nickel chloride enhancement, resulting in a(PDGF--R) by combined immunohistochemistry and
black color product. After methyl green counterstaining,in situ hybridization.
the slides were dehydrated, and coverslipped in Histo-
mount (National Diagnostics, Atlanta, GA, USA).METHODS
Antibodies utilized to detect specific proteins or cell
Breeding types are listed in Table 1. The specificity of each anti-
Breeding, and genotyping of the TSLP transgenic mouse body clone has been established as referenced. For all
strain has previously been described in detail [21]. The samples, negative controls for the immunohistochemis-
study was performed after backcrossing to a C57BL6 try included substituting for the primary antibody an
background for more than eight generations. Male TSLP irrelevant IgG from the same species or phosphate-buf-
transgenic mice were than mated with wild type C57BL6 fered saline (PBS).
females. The procedures used were approved by the local All slides were scored by an observer who was blinded
Animal Care Committee of the University of Washington. to the origin of the histologic specimen. Semiquantitative
scoring of glomerular expression of SMA, type I andExperimental design
IV collagen, and laminin was performed using five grades
A total of 123 mice including 61 TSLP transgenic mice as follows: 0  absent staining; 1  mesangial staining
and 62 wild-type controls were used. Male mice were involving less than 25% of the area examined; 2  seg-
sacrificed at monthly intervals up to seven months of age mental mesangial staining involving 25 to 50% of mesan-
(N  75), female mice were sacrificed at 1, 1.5, 2, 2.5 gial areas present; 3  mesangial staining involving 50
months of age (N  48).
to 75% of the areas examined; and 4 diffuse mesangialThese mice have been evaluated by immunohisto-
staining involving more than 75% of areas examined aschemistry for SMA, collagen type I, collagen type IV,
previously described and illustrated [22]. The number ofand laminin. Expression of PDGF-B chain, PDGF -R,
PCNA positive cells in the glomerular tufts was countedTGF-1 mRNA expression were evaluated by in situ
at a magnification of 400. Both the number of thehybridization. Additionally, a preliminary series of 27
intraglomerular positive cells and the number of glomer-TSLP transgenic and 16 wild-type controls were evalu-
uli were counted and the data were presented as posi-ated for PDGF-A chain and PDGF -R, PDGF-B chain,
tively stained cells per glomerular cross section (gcs).PDGF--R, TGF-1 mRNA by in situ hybridization.
Cells outside the glomerular tufts were not included. At
Renal morphology least 20 consecutive cross sections of glomeruli were
examined using each of the above antibodies. The mor-Renal tissue was fixed in part in 10% neutral-buffered
phometric analysis of glomerular cell numbers has beenformalin and in methyl Carnoy’s solution as described
described previously [21].previously [22]. Fixed tissues were processed, embedded
in paraffin according to standard protocols and sectioned
Molecular probesat 4 m. Slides were stained with periodic acid methena-
The molecular probes used in this study have pre-mine silver (silver), with periodic acid-Schiff’s (PAS), and
viously been described and used for in situ hybridizationhematoxylin and eosin (H&E) using standard histologic
procedures. [30]. These included probes for:
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Table 1. Antibodies used to detect specific antigens in biopsy tissue
Dilution of
Antigen primary
[references] Clone Primary antibody Secondary antibody antibody
PCNA (Ab-1) [24] PC10 Mouse IgG monoclonal antibody anti-human PCNA Biotin-conjugated monoclonal 1:100
(Oncogene Research Products, Cambridge, MA, rat anti-mouse IgG2a
USA) (Caltag Laboratories)
-smooth muscle actin 1A4 Mouse monoclonal IgG2a anti-human -smooth Biotin-conjugated monoclonal 1:25
[25] muscle actin (DAKO, Carpinteria, CA, USA) rat anti-mouse IgG2a
(Caltag Laboratories)
Type I collagen [26] Goat polyclonal antibody anti-human collagen I Biotinylated rabbit anti-goat 1:1000
(Southern Biotechnology, Birmingham, AL, USA) IgG (Vector Laboratories,
Burlingame, CA, USA)
Type IV collagen [27] Goat polyclonal antibody anti-human collagen IV Biotinylated rabbit anti-goat 1:600
(Southern Biotechnology) IgG (Vector Laboratories)
Laminin [28] Rabbit polyclonal antibody anti-rat laminin (mouse Biotinylated goat anti-rabbit 1:800
cross react) (Chemicon, Temecula, CA, USA) IgG (Vector Laboratories)
Mac-2 [29] M3/38 Rat IgG monoclonal antibody anti-mouse Mac-2 Biotinylated goat anti-mouse 1:5000
(CEDARLANE, Hornby, Ontario, Canada) IgG, mouse adsorbed
(Vector Laboratories)
All antigens were immunostained using methyl Carnoy’s fixed tissue, except PCNA and Mac-2 on formalin fixed tissue.
Fig. 1. -Smooth muscle actin (SMA) expression in thymic stromal lymphoprotein (TSLP) transgenic mice and wild-type controls. Immunohisto-
chemistry for SMA in a wild type female (A) and a TSLP transgenic female at the age of 2.5 months (B; original magnification 400). Glomerular
staining is absent in the wild-type control, whereas the TSLP transgenic mouse shows strong expression of SMA in a mesangial pattern. Both
wild-type and transgenic mice show constitutive expression of SMA in vascular smooth muscle cells of arteries and arterioles. Time course of
SMA scores in female (C ) and male mice (D). Symbols are: () control; () transgenic mice.
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Fig. 2. Immunohistochemical staining for ex-
tracellular membrane (ECM). (A–D) Immu-
nohistochemistry for type IV collagen (A, B)
and laminin (C, D) in a wild-type control
(A, C) and a TSLP transgenic female at the
age of 2.5 months (B, D; all original magnifi-
cation 400). TSLP transgenic mice demon-
strated an increase in collagen IV and laminin
in a mesangial pattern as compared to wild
type controls. (E–H ) Immunohistochemistry
for type IV collagen (F), and laminin (H) and
silver stains (E, G) performed on serial sec-
tions of a TSLP male at the age of 5 months (all
orig. 400). The widening of the mesangial
matrix in this case was mainly due to massive
immune deposits, which are silver negative
and do not stain for type IV collagen and
laminin. Note the positive staining in the re-
maining mesangial matrix.
PDGF-A chain: A 536 nucleotides (nt) SmaI fragment PDGF -R: A 1636 nt EcoRI fragment of the mouse
cDNA (GenBank Acc. #M57683: nt 201 to 1837)of the mouse PDGF A-chain cDNA (GenBank Acc.
was cloned into the EcoRI site of pGEM-3Zf#M29464: nt 1 to 906) was cloned into the SmaI
(Promega Biotec). The full-length probe is 1692 nt.site of pGEM-3Zf (Promega Biotec, Madison, WI,
USA). The full-length probe is 592 nt.
PDGF -R: A 2075 bp PstI fragment of the mouse
cDNA (GenBank Acc. #X04367: nt 1667 to 3742)PDGF-B chain: An 806 nt EcoRI fragment of the
was inserted into the PstI site of pGEM-3Zf (Pro-
mouse cDNA that contains a 752 nt fragment of
mega Biotec). The full-length probe is 2131 nt.
mouse B-chain was a gift from C. Stiles (Dana-
Farber Cancer Institute, Boston, MA, USA). It was TGF-1: (gift from H.L. Moses, Dept. Cell Biology,
inserted into the EcoRI site of pGEM-3Zf (Pro- Vanderbilt University, Nashville, TN, USA) [31]. A
mega Biotec). The full-length probe encodes for the 974 nt fragment of the mouse cDNA was inserted
into the SmaI site of pGem7Zf (Promega Biotec).whole PDGF B-chain molecule.
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Fig. 3. Immunohistochemical scores for ECM and PCNA. Time course of mean scores for collagen type IV (A, B), laminin (C, D) and mean
number of PCNA positive cells per glomerular cross section (gcs, E, F ) in female (A, C, E) and male mice (B, D, F). Symbols are: () control
mice; () transgenic mice.
After linearization 35S antisense and sense (negative con- -R, or TGF-1), combined immunohistochemistry and
trol) riboprobes were produced, using reagents from Pro- in situ hybridization were performed as previously de-
mega, and 35S UTP, from NEN (Boston, MA, USA) [32]. scribed [33]. Slides were first hybridized with antisense
and sense riboprobes for detection of TGF-1, PDGF-B
In situ hybridization chain or PDGF--R mRNA. After stringency washes,
The in situ hybridization protocols have recently been slides were immunostained for macrophages (Mac-2)
described in detail [33, 34]. Negative controls included using the DAB detection system without nickel chloride
hybridization performed on replicate tissue sections us- enhancement to produce a brown reaction product. Fol-
ing the sense riboprobe. lowing immunostaining, slides were washed, dehydrated
The intensity of intraglomerular expression for each and dipped in NTB-2 emulsion.
transcription was graded semiquantitatively by an ob-
server blinded to origin of the histologic specimen as Statistical analysis
follows: 0  absent, 1  mild (a few positive cells), 2 
All values are expressed as the mean standard devia-moderate (several positive cells in a segmental distribu-
tion (SD). Using the SPSS program, Version 10.0 fortion within the glomerulus), and 3  severe (many posi-
Windows (SPSS Inc., Chicago, IL, USA), the non-para-tive cells in a diffuse distribution).
metric Mann-Whitney U-test was used to compare the
Combined immunohistochemistry and in situ hybridization means between groups. The number of macrophages
expressing PDGF-B chain or TGF-1 mRNA was com-To identify monocyte/macrophage expression of spe-
cific growth factors and receptors (PDGF B-chain, PDGF- pared for each of the study time points by one-way analy-
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study [21]. Renal lesions were characterized by mesan-
gial expansion due to matrix and immune complex depo-
sition, thickened and split capillary walls with prominent
immune deposits and cellular interposition and macro-
phage influx, which are typical features of cryoglobuli-
nemic MPGN. All TSLP transgenic mice demonstrated
a widening of the mesangial area after the age of one
month, which was more prominent in female than in
males at early time points. Massive deposition of immune
complexes were present also in the capillary walls of
both genders of transgenic mice, which sometimes led
to complete capillary occlusion with progression of the
disease. In the most severe cases, the mesangium was
expanded and most of the capillary lumina were oc-
cluded. In contrast, globally sclerotic glomeruli were not
found in either gender of transgenic mice even at late
time points. The progression of renal lesion and the
disease course were more pronounced and more acceler-
ated in female than in male mice.
Glomerular expression of -smooth muscle actin
is increased in TSLP transgenic mice
-Smooth muscle actin is expressed by smooth muscle
cells of the arterial wall in normal kidneys, as well as
by mesangial cells during renal development, and by
activated mesangial cells during glomerular injury [22].
All renal specimens from TSLP transgenic mice and con-
trols demonstrated intense staining for SMA by smooth
muscle cells in arterial walls in the interstitium. In most
controls SMA staining was restricted to these sites
(Fig. 1A). However, a few glomeruli in control animals
demonstrated mesangial SMA expression, usually in
a segmental distribution within the glomerular tuft. In
contrast, TSLP transgenic mice of both genders exhibited
increased SMA expression in a mesangial pattern be-
ginning at the age of one month. Female TSLP transgenic
mice demonstrated a constant increase of SMA protein
expression through the course of the disease (0.9  0.2
Fig. 3. (Continued) in TSLP transgenic mice vs. 0.2  0.1 in controls at
month 2.5, P 	 0.01, Fig. 1C). SMA immunostaining
in male transgenic mice was only slightly elevated at
one month of age, but rose progressively and peaked at
month 5 (1.3  0.2 in TSLP transgenic mice vs. 0.1 sis of variance (ANOVA) using Tukey’s post-hoc test.
0.1 in controls, P 	 0.05), and then gradually decreasedAdditionally, the non-parametric Spearman rank corre-
(Fig. 1D). At the age of one month female mice demon-lation coefficients was used to determine the association
strated higher scores than male mice. No apparentbetween PDGF mRNA score and the number of glomer-
SMA expression was observed in interstitial cells ofular proliferating cells among each group.
TSLP transgenic mice as well as of control mice, and
tubular epithelium was negative in the well preserved
tubulointerstitium.RESULTS
Morphology Deposition of extracellular matrix is associated with
increased type IV collagen and laminin proteinGlomerular pathologic alterations of TSLP transgenic
expression in TSLP transgenic micemice during the time course of the study, which covers
first 2.5 months of age in female and the first seven The area and percentage of glomerular ECM was as-
sessed by morphometric analysis on silver methenaminemonths of age in males, were described in a previous
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stained sections [21]. An increased deposition of extra-
cellular matrix was demonstrated early in the disease
course and reached a plateau in both genders [21]. To
assess the sequential contribution of individual ECM
components, immunohistochemical staining was per-
formed for type I collagen, type IV collagen and laminin.
Control mice of both genders demonstrated immuno-
staining of type IV collagen in the glomerular and tubular
basement membranes. Glomerular staining for type IV
collagen in control mice was focal in distribution, which
had no apparent change during the ages studied (Figs.
2A and 3 A, B). A similar staining pattern for laminin
was observed in control kidneys (Figs. 2C and 3 C, D). In
contrast, TSLP transgenic mice demonstrated increased
staining for type IV collagen and laminin predominantly
in the mesangium (Fig. 2 B, D, F, H). In the most severe
cases, the mesangium was widened due to both matrix
accumulation and massive deposition of immune depos-
its, at times associated with complete capillary occlusion
[21]. Although the expanded mesangial area in trans-
genic mice was due to increased matrix deposition, this
did not advance to global sclerosis, as such glomeruli
were absent throughout the time course of the disease
that was studied [21]. Areas occupied by immune depos-
its, as determined by correlative electron microscopy,
did not stain with the silver methenamine reagent, and
these areas also were unreactive with antibodies to detect
both collagen type IV and laminin accumulation (Fig.
Fig. 4. Percentage of PCNA positive cells to the total glomerular cells2 F, H). In female TSLP transgenic mice, mesangial in female mice (A ) and male mice (B ). The proportion of PCNA
immunostaining for type IV collagen and laminin rose positive cells to the cell number increased with the time course of the
disease in both genders of TSLP transgenic mice (), but not in controlgradually from one month of age up to month 2.5 (type
mice ().IV collagen, 3.1  0.1 in TSLP transgenic mice vs. 1.9 
0.1 in controls, P 	 0.01; Fig. 3A; laminin, 2.7  0.4 in
0.05). PCNA positive nuclei were present in the mesan-TSLP transgenic mice vs. 0.5  0.4 in controls, P 	 0.01;
gium, at the periphery of capillary loops, and occasion-Fig. 3C). In male TSLP transgenic mice, laminin and
ally in parietal epithelial cells.type IV collagen scores reached a plateau at month 3
Although an increase in PCNA positive cells per glo-(type IV collagen, 3.0  0.1 in TSLP transgenic mice vs.
merulus was demonstrated in TSLP transgenic mice, the1.9  0.1 in controls, P 	 0.01; Fig. 3B; laminin, 2.7 
total cell number per glomerulus was increased signifi-0.1 in TSLP transgenic mice vs. 0.6  0.3 in controls,
cantly in TSLP transgenic mice [21]. Therefore, we as-P 	 0.05; Fig. 3D). Glomerular staining for collagen I
sessed the percentage of PCNA-positive cells with re-was absent in both controls and TSLP transgenic mice
spect to the total glomerular cell number. The proportion(data not shown).
of PCNA-positive cells compared to the total glomerular
cells in female transgenic mice increased progressivelyAn increased number of proliferating glomerular cells
to month 2.5 (5.5  2.1% in month 1, 13.3  5.2% incharacterizes the increased glomerular cellularity in
month 2.5). Male transgenic mice had a gradual increaseTSLP transgenic mice
in percentage of proliferative cells up to month 7 (3.3 
A significant increase in PCNA positive cells was dem- 1.3% in month 1, 7.8  4.3% in month 7). In contrast,
onstrated beginning at month 1 in both genders of TSLP the proportion of PCNA-positive cells per glomerulus
transgenic mice, and was more pronounced in females did not change in control groups.
at this time point (Fig. 4). In male TSLP transgenic mice,
PDGF-B chain and PDGF--R mRNA is increased inglomerular cell proliferation reached a plateau at three
TSLP transgenic mice and correlates with glomerularmonths of age (3.4  1.3 PCNA positive cells/gcs vs.
cell proliferation0.3  0.2 in controls, P 	 0.05), while female transgenic
mice had a gradual elevation up to month 2.5 (6.2  2 Representative in situ hybridization results including
sense controls are illustrated in Figure 5 and Figure 6.PCNA positive cells/gcs vs. 0.3  0.1 in controls, P 	
Fig. 5. In situ hybridization for PDGF-B chain
mRNA. In situ hybridization using a PDGF-B
chain antisense riboprobe (A–D) and a sense
riboprobe (E ) performed on tissue sections
from wild-type controls (A, female; C, male)
and a 2.5-month-old TSLP transgenic female
(B) and a TSLP transgenic male at month
6 (D, all orig. 400). TSLP transgenic mice
showed a prominent increase in number of
cells and intensity of the signal in the mesan-
gium and in parietal epithelial cells. Minimal
background accumulation of silver grains is
present in E.
Fig. 6. In situ hybridization for PDGF--R
mRNA. In situ hybridization using a PDGF-
-R antisense riboprobe (A–D) and a sense
riboprobe control (E ) performed on tissue
sections from wild-type controls (A, female;
C, male) and a 1.5-month-old TSLP transgenic
female (B) and a TSLP transgenic male at
month 3 (D, all orig. 400). Up-regulated ex-
pression of PDGF--R mRNA is demon-
strated in the TSLP mice of both genders.
Minimal background accumulation of silver
grains is present in E.
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Fig. 7. Semiquantitative PDGF mRNA scores. Semiquantitative analysis of glomerular PDGF-B chain mRNA (A, B) and PDGF--R mRNA
(C, D) in female (A, C) and male mice (B, D) demonstrating higher levels of expression for both PDGF-B chain and its receptor in TSLP
transgenic mice. Symbols are: () transgenic mice; () control mice.
A preliminary series of animals (Methods section) was scattered tubulointerstitial cells both in wild-type and
TSLP transgenic mice without apparent differences be-studied by in situ hybridization for expression of PDGF
A-chain, PDGF-B chain and their receptors, PDGF--R tween the two groups. As shown in Figure 7, the glomeru-
lar expression patterns of PDGF-B chain and PDGF--Rand -R. Glomerular expression of PDGF A-chain was
not detected and PDGF--R was present in a very low mRNA in controls did not significantly vary over time
between the two genders. In contrast, the expression ofnumber of glomeruli, whereas a prominent induction of
PDGF-B chain and PDGF--R became apparent. There- PDGF-B chain or PDGF--R mRNA reached a plateau
after three months of age in TSLP transgenic malesfore, these two factors were chosen for further study in
the current prospective animal series. (Fig. 7 B, D), whereas female mice demonstrated high
expression for each probe as early as the first month ofGlomeruli of wild-type controls showed either absent
or weak mesangial expression of PDGF-B chain (Fig. age and this remained elevated for the duration of time
course of the study (Fig. 7 A, C). In TSLP transgenic5 A, C) and PDGF -R mRNA (Fig. 6 A, C). In contrast,
TSLP transgenic mice exhibited increased expression of mice, there was a moderate to strong positive correlation
between the number of glomerular proliferating cellsPDGF-B chain and PDGF -R in both the mesangium
and the parietal epithelial cells (Fig. 5 B, D). Expression and the intensity of glomerular expression for PDGF
B-chain (Spearman r  0.63, P  0.002 for females;of PDGF-B chain and PDGF -R mRNA was found in
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Fig. 8. (A ) Correlation between PCNA-positive cells per glomerular cross section (gcs) and PDGF-B chain mRNA scores in female mice.
(Transgenic mice, r  0.63, P 
 0.01; Control mice, r  0.23, P  0.31). (B) Correlation between PCNA-positive cells and PDGF-B chain mRNA
scores in male mice (transgenic mice, r  0.64, P 
 0.001; control mice, r  0.05, P  0.76). (C ) Correlation between PCNA-positive cells and
PDGF--R mRNA scores in female mice (transgenic mice, r  0.70, P 
 0.001; control mice, r  0.18, P  0.42). (D) Correlation between
PCNA-positive cells and PDGF--R mRNA scores in male mice (transgenic mice, r  0.75, P 
 0.001; control mice, r  0.16, P  0.37). The
correlation between cell proliferation as measured by PCNA expression and PDGF synthesis was significant in both genders of TSLP transgenic
mice. Symbols are: () transgenic mice; () control mice.
Fig. 8A, Spearman r 0.64, P	 0.001 for males; Fig. 8B) expression, they did not manifest a significant glomerular
proliferative response (Fig. 8).or PDGF--R mRNA (Spearman r  0.70, P 	 0.001
for females; Fig. 8C, Spearman r  0.75, P 	 0.001 for
TGF-1 mRNA is increased in TSLP transgenic micemales; Fig. 8D). In contrast, the association between
those variables in control groups was very weak (PDGF As TGF-1 is thought to be of major importance dur-
ing the deposition of ECM, the expression of TGF-1B-chain, Spearman r  0.23, P  0.31 for females,
Fig. 8A, and Spearman r  0.05, P  0.76 for males; mRNA was studied by in situ hybridization. Weak ex-
pression of TGF-1 mRNA in a mesangial pattern wasFig. 8B; PDGF--R, Spearman r  0.18, P  0.42 for
females, Fig. 8C, and Spearman r  0.16, P  0.37 for detected in control mice (Fig. 9 A, C). Female transgenic
mice showed increased glomerular expression of TGF-1males; Fig. 8D). Although a few control mice showed
elevated levels of PDGF-B chain and PDGF--R mRNA mRNA beginning at the age of 1.5 months (Figs. 9B and
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Fig. 9. In situ hybridization for TGF-1
mRNA. In situ hybridization using a TGF-1
antisense riboprobe (A–D) and a sense ribo-
probe control (E ) performed on tissue sec-
tions from wild-type controls (A, female; C,
male) and a 2.5-month-old TSLP transgenic
female (B) and a TSLP transgenic male at the
age of 6 months (D, all orig. 400). Only a
weak signal is present in wild-type controls,
while there is prominent up-regulated expres-
sion of TGF-1 in TSLP transgenic mice. Min-
imal background accumulation of silver grains
is present in E.
10A). In contrast, TSLP transgenic males demonstrated chain mRNA was expressed by intrinsic renal cells
an increased expression beginning at four months up to that did not express the macrophage marker (Fig. 11A).
seven months of age (Figs. 9D and 10B), but did not show Macrophages expressing PDGF--R mRNA were not
significant changes from the normal expression pattern detected in any of the transgenic mice (Fig. 11B). Figure
prior to month 3. 12 shows the percentage of the glomerular macrophages
that express these growth factors at the different time
Intraglomerular macrophages express PDGF-B chain
points studied. The proportion of glomerular macro-
and TGF-1 mRNA but not PDGF--R mRNA
phages expressing PDGF-B chain and TGF-1 mRNA
To identify glomerular monocytes/macrophages as a did not show significant differences when analyzed at
potential source of growth factors or the PDGF  recep- different time points.
tor, we combined immunohistochemical labeling of Mac-2
expressing macrophages with in situ hybridization for
PDGF-B chain, PDGF--R, and TGF-1 mRNA. Renal DISCUSSION
tissues obtained from control TSLP wild-type mice were
A new transgenic mouse model of cryoglobulinemicnot included in this part of the study, because glomerular
MPGN gave us the opportunity to describe the temporalmacrophages in wild-type mice were barely detected in
changes in expression of several members of the PDGFprevious experiments [21].
family and TGF-1, in combination with components ofA significant proportion (approximately half) of intra-
the ECM and markers of cell activation/proliferation, inglomerular monocytes/macrophages manifesting Mac-2
this disease process [21]. The glomerular lesion in TSLPantigen expressed TGF-1 mRNA (Figs. 11C and Fig. 12).
transgenic mice is characterized by widening of the mes-In contrast, only a small percentage (less than 10%) of
angium due to an expanded mesangial matrix and depo-glomerular Mac-2 expressing monocytes/macrophages
sition of immune deposits, increased glomerular size withexpressed PDGF B-chain mRNA during any of the time
points studied (Figs. 11A and 12). Most of the PDGF-B an increase of the absolute glomerular cell number, sub-
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whereas collagen type I was not detectable. These results
are consistent with data in human MPGN, which describe
increased expression type IV collagen and laminin in the
glomerular mesangial areas and the peripheral capillary
walls [36, 37].
In contrast to the rare occurrence or absence to the ex-
pression of PDGF-A chain and PDGF--R, as revealed
by our pilot studies, there is prominent induction of
PDGF-B chain and the corresponding receptor PDGF-
-R in this disease model. The distribution patterns for
this ligand/receptor pair were very similar in mesangial
areas, and parietal epithelial cells. PDGF-B chain and
-R correlated significantly with the number of prolifer-
ating glomerular cells. Up-regulation of PDGF protein
previously has shown to correlate with glomerular mes-
angial cell proliferation [38–40]. Additionally, the ex-
pression of PDGF-B chain and -R paralleled an in-
crease in extracellular matrix. The importance of PDGF-B
chain in the regulation of glomerular extracellular ma-
trix accumulation, as well as in mesangial cell prolifera-
tion has been demonstrated by several interventional
studies [9, 15, 41]. Experiments with infusion of PDGF-B
chain in the anti-Thy1.1 model in rats [41] or transfection
of PDGF-B chain cDNA to rats [15] induced selective
glomerular mesangial cell proliferation and matrix accu-
mulation redundant [8, 15]. Furthermore, blockade by
a neutralizing antibody to PDGF reduced mesangial cell
proliferation and largely prevented the increased deposi-
tion extracellular matrix in anti-Thy1.1 glomerulonephri-
tis [9]. Here we demonstrate the expression of PDGF-B
chain and its receptor in a mouse model with a membra-
Fig. 10. Semiquantitative analysis of glomerular TGF-1 mRNA noproliferative pattern of injury and confirm a correla-scores in female (A) and male (B) mice showing higher levels of expres-
tion with glomerular cell proliferation and matrix deposi-sion of TGF-1 in the TSLP transgenic mice. Symbols are: () trans-
genic mice; () control mice. tion. Induction of PDGF-B chain was demonstrated
earlier in females as compared to males, consistent with
more severe lesions that occur in females at earlier time
points.
endothelial immune deposits in peripheral capillary walls, Transforming growth factor- also has been shown to
and splitting of capillary basement membranes. play an important role during the development of mes-
We documented that a change in the mesangial cell angial matrix expansion [16, 19]. Increased expression
phenotype characterized by de novo expression of SMA of TGF-1 has been reported in several experimental
was found early in the disease course in both genders of models as well as in human glomerulonephritis [42–48].
TSLP transgenic mice and showed a progressive increase One study suggested a potential role for direct stimula-
in TSLP transgenic males. This phenotypic change has tion of glomerular cells by immune complexes composed
previously been described in other rodent models of re- of IgG and IgA, which then trigger the formation of ECM
nal injury [8, 25, 35], and in human glomerulonephritis via Fc receptors, utilizing pathways involving TGF-1
including MPGN [22]. In TSLP transgenic mice this change [49]. The actual stimulus for TGF-1 production in our
is likely related to activation of mesangial cells following model or in human disease is not yet known. It is clear
deposition of immune complexes. that the time course of TGF-1 mRNA paralleled the ex-
An increase of extracellular mesangial matrix devel- pression of extracellular matrix proteins in our model,
ops early in the development of the disease in TSLP trans- consistent with established paradigms.
genic mice, but does not progress to global glomerulo- Our study also established that the intraglomerular
sclerosis, at least within the time frame studied. Here monocytes/macrophages may be a source for some of the
we demonstrated that this matrix accumulation is due PDGF-B chain and TGF-1 activity in the glomerular
injury. TSLP transgenic mice develop significant mono-in part to deposition of collagen type IV, and laminin,
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Fig. 11. Combined immunohistochemistry and in situ hybridization. Combined immunohistochemical labeling (brown) of Mac-2 expressing
monocytes/macrophages with in situ hybridization (black grains) for PDGF-B chain (A), PDGF--R (B) and TGF-1 (C ), and a sense riboprobe
control for PDGF-B chain (D), PDGF--R (E ), and TGF-1 (F ). (A) PDGF-B chain mRNA is present in a Mac-2 expressing macrophage
(arrow), but most glomerular cells expressing PDGF-B chain mRNA do not express monocyte/macrophage marker (arrowheads). This glomerulus
was obtained from a female transgenic mouse at the age of 2.5 months. (B) Cells with up-regulated PDGF--R mRNA were numerous (arrowheads),
but these cells could not be identified as monocytes/macrophages (arrow). Immunolabeled monocytes/macrophages in brown revealed no colabeling
with the PDGF--R mRNA probe. This glomerulus was obtained from a male transgenic mouse at the age of 3 months. (C) TGF-1 mRNA expressing
monocyte/macrophage (arrow) and TGF-1 mRNA expressing cell which does not express the monocyte/macrophage marker (arrowhead), within
a glomerulus obtained from a female transgenic mouse at the age of 2 months. Minimal background accumulation of silver grains is present in D,
E and F (original magnification, 1000).
cyte/macrophage infiltration in glomeruli [21]. Although ity of cells producing PDGF-B chain were mesangial
cells [40].monocytes/macrophage are known to be one of the ma-
Based on the above, these are several principal pointsjor sources of growth factors including PDGF and TGF-
to be gleaned from this study. First, the findings demon-[50, 51], the contribution of infiltrating macrophages
strating expression and presumptive activities of PDGF-Bcompared with that of renal intrinsic cells in the synthesis
chain and its receptor and TGF-1 in this model ofof growth factors currently has not been established. In
MPGN conform to paradigms established in the ratour model, a significant proportion of Mac-2 expressing
model of anti-Thy1 of mesangiolytic injury and repair.monocytes/macrophages expressed TGF-1, which sug-
We believe this is important because it demonstratesgests increased TGF-1 activity may be the result of both
that these paradigms are generalizable to glomerular
paracrine secretion and autocrine production in this
and mesangial injuries other than mesangiolysis, and to
model. In contrast, the percentage of monocytes/macro- species other than the rat. The close morphologic similar-
phages expressing PDGF B-chain was small in TSLP ity between renal injury in the TSLP transgenic mouse
transgenic mice, and it is it unlikely that they are the and human cryoglobulinemic MPGN means it is likely,
major source of increased glomerular PDGF. Previous though not yet proven, that similar expression of these
studies demonstrated that in the rat anti-Thy1.1 model growth factors occurs at similar stages of injury in the
of mesangial proliferative glomerulonephritis, more than human disease. The predictable injury course in these
90% of the glomerular cells immunostaining for PDGF mice, which occurs notably early in female mice, suggests
it would serve as a good model system to test interven-B-chain also expressed SMA, indicating that the major-
Taneda et al: Growth factors in murine MPGN 589
ACKNOWLEDGMENTS
This work was supported in part by grants from the Northwest
Kidney Centers Foundation, the KIDNEEDS foundation, and pilot
project funds from the National Institutes of Health (U19A141320).
Reprint requests to Dr. Charles E. Alpers, Department of Pathology,
University of Washington Medical Center, Box 356100, 1959 NE Pacific
Street, Seattle, Washington 98195, USA.
E-mail: calp@u.washington.edu
REFERENCES
1. Brouet JC, Clauvel JP, Danon F, et al: Biologic and clinical
significance of cryoglobulins. A report of 86 cases. Am J Med 57:
775–788, 1974
2. Gorevic PD, Kassab HJ, Levo Y, et al: Mixed cryoglobulinemia:
Clinical aspects and long-term follow-up of 40 patients. Am J Med
69:287–308, 1980
3. Tarantino A, Campise M, Banfi G, et al: Long-term predictors
of survival in essential mixed cryoglobulinemic glomerulonephritis.
Kidney Int 47:618–623, 1995
4. Monti G, Saccardo F, Pioltelli P, et al: The natural history of
cryoglobulinemia: Symptoms at onset and during follow-up. A
report by the Italian Group for the Study of Cryoglobulinemias
(GISC). Clin Exp Rheumatol 13(Suppl 13):S129–S133, 1995
5. Mazzucco G, Monga G, Casanova S, et al: Cell interposition in
glomerular capillary walls in cryoglobulinemic glomerulonephritis
(CRYGN). Ultrastructural investigation of 23 cases. Ultrastruct
Pathol 10:355–361, 1986
6. D’Amico G, Fornasieri A: Cryoglobulinemic glomerulonephritis:
A membranoproliferative glomerulonephritis induced by hepatitis
C virus. Am J Kidney Dis 25:361–369, 1995
7. D’Amico G: Renal involvement in hepatitis C infection: Cryo-
globulinemic glomerulonephritis. Kidney Int 54:650–671, 1998
8. Floege J, Burns MW, Alpers CE, et al: Glomerular cell prolifera-
tion and PDGF expression precede glomerulosclerosis in the rem-
nant kidney model. Kidney Int 41:297–309, 1992
9. Johnson RJ, Raines EW, Floege J, et al: Inhibition of mesangial
cell proliferation and matrix expansion in glomerulonephritis in
the rat by antibody to platelet-derived growth factor. J Exp Med
175:1413–1416, 1992
10. Barnes JL, Hevey KA: Glomerular mesangial cell migration.
Response to platelet secretory products. Am J Pathol 138:859–
866, 1991
11. Ross R: Platelet-derived growth factor. Lancet 1:1179–1182, 1989
12. Silver BJ, Jaffer FE, Abboud HE: Platelet-derived growth factor
synthesis in mesangial cells: Induction by multiple peptide mito-
gens. Proc Natl Acad Sci USA 86:1056–1060, 1989
Fig. 12. Extent of intraglomerular monocyte/macrophage and expres- 13. Nakamura T, Ebihara I, Nagaoka I, et al: Renal platelet-derived
sion of PDGF B-chain () or TGF-1 () mRNA. Data were obtained growth factor gene expression in NZB/W F1 mice with lupus and
from combined immunohistochemistry and in situ hybridization as de- ddY mice with IgA nephropathy. Clin Immunol Immunopathol 63:
tailed in the Methods section. Data are expressed as percent of the total 173–181, 1992
number of PDGF B-chain positive or TGF-1–positive macrophages/all 14. Madri JA, Marx M: Matrix composition, organization and soluble
macrophages in glomeruli within an entire tissue section of female TSLP factors: Modulators of microvascular cell differentiation in vitro.
mice (A) and of male TSLP mice (B). Kidney Int 41:560–565, 1992
15. Isaka Y, Fujiwara Y, Ueda N, et al: Glomerulosclerosis induced
by in vivo transfection of transforming growth factor-beta or plate-
let-derived growth factor gene into the rat kidney. J Clin Invest 92:
2597–2601, 1993tions aimed at interrupting growth factor pathways in
16. Border WA, Okuda S, Languino LR, et al: Transforming growthMPGN. These are differences in disease expression in factor-beta regulates production of proteoglycans by mesangial
these mice that are gender related, which is not a recog- cells. Kidney Int 37:689–695, 1990
17. Nakamura T, Miller D, Ruoslahti E, et al: Production of extra-nized feature of human cryoglobulinemic MPGN. We
cellular matrix by glomerular epithelial cells is regulated by trans-hope that further study of this feature may provide useful
forming growth factor-beta 1. Kidney Int 41:1213–1221, 1992
insights into the pathogenesis and potential treatment 18. Roberts AB, McCune BK, Sporn MB: TGF-beta: Regulation of
extracellular matrix. Kidney Int 41:557–559, 1992of this form of glomerulonephritis. The detailed charac-
19. Border WA, Noble NA: Transforming growth factor beta in tissueterization of a murine model of MPGN should allow it
fibrosis. N Engl J Med 331:1286–1292, 1994
to serve as a baseline system for genetic manipulations 20. Friend SL, Hosier S, Nelson A, et al: A thymic stromal cell line
supports in vitro development of surface IgM B cells and pro-aimed at defining the pathophysiology of this disorder.
Taneda et al: Growth factors in murine MPGN590
duces a novel growth factor affecting B and T lineage cells. Exp analysis of extracellular components in the glomerular sclerosis of
patients with glomerulonephritis. Clin Nephrol 34:239–246, 1990Hematol 22:321–328, 1994
21. Taneda S, Segerer S, Hudkins KL, et al: Cryoglobulinemic glo- 37. Oomura A, Nakamura T, Arakawa M, et al: Alterations in the
extracellular matrix components in human glomerular diseases.merulonephritis in thymic stromal lymphopoietin transgenic mice.
Am J Pathol 159:2355–2369, 2001 Virchows Arch A Pathol Anat Histopathol 415:151–159, 1989
38. Gesualdo L, Pinzani M, Floriano JJ, et al: Platelet-derived22. Alpers CE, Hudkins KL, Gown AM, et al: Enhanced expression
growth factor expression in mesangial proliferative glomerulo-of muscle-specific actin in glomerulonephritis. Kidney Int 41:1134–
nephritis. Lab Invest 65:160–167, 19911142, 1992
39. Floege J, Topley N, Resch K: Regulation of mesangial cell prolif-23. Segerer S, Cui Y, Eitner F, et al: Expression of chemokines and
eration. Am J Kidney Dis 17:673–676, 1991chemokine receptors during human renal transplant rejection. Am
40. Iida H, Seifert R, Alpers CE, et al: Platelet-derived growth factorJ Kidney Dis 37:518–531, 2001
(PDGF) and PDGF receptor are induced in mesangial proliferative24. Miyachi K, Fritzler MJ, Tan EM: Autoantibody to a nuclear
nephritis in the rat. Proc Natl Acad Sci USA 88:6560–6564, 1991antigen in proliferating cells. J Immunol 121:2228–2234, 1978
41. Floege J, Eng E, Young BA, et al: Infusion of platelet-derived25. Johnson RJ, Iida H, Alpers CE, et al: Expression of smooth
growth factor or basic fibroblast growth factor induces selectivemuscle cell phenotype by rat mesangial cells in immune complex
glomerular mesangial cell proliferation and matrix accumulationnephritis. Alpha-smooth muscle actin is a marker of mesangial cell
in rats. J Clin Invest 92:2952–2962, 1993proliferation. J Clin Invest 87:847–858, 1991
42. Okuda S, Languino LR, Ruoslahti E, et al: Elevated expression26. Fouser L, Iruela-Arispe L, Bornstein P, et al: Transcriptional
of transforming growth factor-beta and proteoglycan productionactivity of the alpha 1(I)-collagen promoter is correlated with the
in experimental glomerulonephritis. Possible role in expansion offormation of capillary-like structures by endothelial cells in vitro.
the mesangial extracellular matrix. J Clin Invest 86:453–462, 1990J Biol Chem 266:18345–18351, 1991
43. Pankewycz OG, Guan JX, Bolton WK, et al: Renal TGF-beta27. Manthorpe M, Engvall E, Ruoslahti E, et al: Laminin promotes
regulation in spontaneously diabetic NOD mice with correlationsneuritic regeneration from cultured peripheral and central neurons.
in mesangial cells. Kidney Int 46:748–758, 1994J Cell Biol 97:1882–1890, 1983
44. Nakamura T, Ebihara I, Fukui M, et al: Renal expression of28. Moiseeva EP, Spring EL, Baron JH, et al: Galectin 1 modulates
mRNAs for endothelin-1, endothelin-3 and endothelin receptorsattachment, spreading and migration of cultured vascular smooth
in NZB/W F1 mice. Ren Physiol Biochem 16:233–243, 1993muscle cells via interactions with cellular receptors and compo- 45. Iwano M, Akai Y, Fujii Y, et al: Intraglomerular expression ofnents of extracellular matrix. J Vasc Res 36:47–58, 1999 transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients29. Rosenberg I, Cherayil BJ, Isselbacher KJ, et al: Mac-2-binding with glomerulonephritis: Quantitative analysis by competitive
glycoproteins. Putative ligands for a cytosolic beta-galactoside lec- polymerase chain reaction. Clin Exp Immunol 97:309–314, 1994
tin. J Biol Chem 266:18731–18736, 1991 46. Yoshioka K, Takemura T, Murakami K, et al: Transforming
30. Seifert RA, Alpers CE, Bowen-Pope DF: Expression of platelet- growth factor-beta protein and mRNA in glomeruli in normal and
derived growth factor and its receptors in the developing and adult diseased human kidneys. Lab Invest 68:154–163, 1993
mouse kidney. Kidney Int 54:731–746, 1998 47. Yamamoto T, Nakamura T, Noble NA, et al: Expression of trans-
31. Pelton RW, Hogan BL, Miller DA, et al: Differential expression forming growth factor beta is elevated in human and experimental
of genes encoding TGFs beta 1, beta 2, and beta 3 during murine diabetic nephropathy. Proc Natl Acad Sci USA 90:1814–1818, 1993
palate formation. Dev Biol 141:456–460, 1990 48. Shankland SJ, Pippin J, Pichler RH, et al: Differential expression
32. Alpers CE, Hudkins KL, Ferguson M, et al: Platelet-derived of transforming growth factor-beta isoforms and receptors in ex-
growth factor A-chain expression in developing and mature human perimental membranous nephropathy. Kidney Int 50:116–124, 1996
kidneys and in Wilms’ tumor. Kidney Int 48:146–154, 1995 49. Lopez-Armada MJ, Gomez-Guerrero C, Egido J: Receptors for
33. Hudkins KL, Le QC, Segerer S, et al: Osteopontin expression in immune complexes activate gene expression and synthesis of ma-
human cyclosporine toxicity. Kidney Int 60:635–640, 2001 trix proteins in cultured rat and human mesangial cells: Role of
34. Segerer S, Cui Y, Hudkins KL, et al: Expression of the chemokine TGF-beta. J Immunol 157:2136–2142, 1996
monocyte chemoattractant protein-1 and its receptor chemokine 50. Mornex JF, Martinet Y, Yamauchi K, et al: Spontaneous expres-
receptor 2 in human crescentic glomerulonephritis. J Am Soc sion of the c-sis gene and release of a platelet-derived growth
Nephrol 11:2231–2242, 2000 factorlike molecule by human alveolar macrophages. J Clin Invest
35. Young BA, Johnson RJ, Alpers CE, et al: Cellular events in 78:61–66, 1986
the evolution of experimental diabetic nephropathy. Kidney Int 51. Assoian RK, Fleurdelys BE, Stevenson HC, et al: Expression
47:935–944, 1995 and secretion of type beta transforming growth factor by activated
human macrophages. Proc Natl Acad Sci USA 84:6020–6024, 198736. Funabiki K, Horikoshi S, Tomino Y, et al: Immunohistochemical
